Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. They aim to support those early-stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.
13
Total Investments
11
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Pharmaceutical
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Negev Capital
Recent Investments (13)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Post-IPO Equity | •••••• | Jun 2024 | |
| Post-IPO Equity | •••••• | Jul 2023 | |
| Series B | •••••• | Dec 2022 | |
| Post-IPO Equity | •••••• | Dec 2022 | |
| Seed Round | •••••• | Oct 2022 | |
•••• ••••
|
Seed Round | •••••• | Jun 2022 |
|
•••• ••••
|
Series A | •••••• | Feb 2022 |
|
•••• ••••
|
Seed Round | •••••• | Feb 2022 |
|
•••• ••••
|
Seed Round | •••••• | Nov 2021 |
|
•••• ••••
|
Seed | •••••• | Sep 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
